Source:http://linkedlifedata.com/resource/pubmed/id/17603516
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2007-8-16
|
| pubmed:abstractText |
We evaluated long-term toxicities and outcomes in 96 patients with chronic phase chronic myeloid leukemia treated with a single bone marrow allograft regimen. Conditioning was cytosine arabinoside, cyclophosphamide (120 mg/kg) and single fraction total body irradiation (500 cGy). Median follow-up was 12.8 years (0.4-19.9 years). Graft failure occurred in one patient, nonfatal veno-occlusive disease in 13 patients (14%). Overall incidences of acute (a) and chronic (c) graft-vs-host disease (GVHD) were 77 and 63%. The 100-day and 1-year transplant-related mortality (TRM) were 1 and 9.2%, respectively, with no change through 5 years. Five- and 10-year event-free survival rates were 56 and 49%, overall survival (OS) rates 72 and 70%, respectively. Forty patients have relapsed: 8 cytogenetic (20%), 10 hematologic (25%) and 22 molecular (55%). Most have been salvaged with donor-leukocyte infusion, second transplants and/or imatinib therapy. Survival was worse for patients transplanted >2 years from diagnosis (10-year OS 56 vs 78%, P=0.01), for patients over 50 years old (10-year OS 44 vs 75%, P=0.05) and for patients without cGVHD (10-year OS 53 vs 86%, P<0.001). This regimen resulted in successful engraftment, low risk of TRM and long-term survival. In an era when imatinib is first line therapy, this regimen offers a potentially low-toxicity, highly successful alternative in the event of poor imatinib response.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
40
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
423-30
|
| pubmed:meshHeading |
pubmed-meshheading:17603516-Adolescent,
pubmed-meshheading:17603516-Adult,
pubmed-meshheading:17603516-Bone Marrow Transplantation,
pubmed-meshheading:17603516-Cyclophosphamide,
pubmed-meshheading:17603516-Cytarabine,
pubmed-meshheading:17603516-Female,
pubmed-meshheading:17603516-Follow-Up Studies,
pubmed-meshheading:17603516-Graft vs Host Disease,
pubmed-meshheading:17603516-Humans,
pubmed-meshheading:17603516-Leukemia, Myeloid, Chronic-Phase,
pubmed-meshheading:17603516-Male,
pubmed-meshheading:17603516-Middle Aged,
pubmed-meshheading:17603516-Recurrence,
pubmed-meshheading:17603516-Retrospective Studies,
pubmed-meshheading:17603516-Salvage Therapy,
pubmed-meshheading:17603516-Survival Analysis,
pubmed-meshheading:17603516-Transplantation, Homologous,
pubmed-meshheading:17603516-Transplantation Conditioning,
pubmed-meshheading:17603516-Treatment Outcome,
pubmed-meshheading:17603516-Whole-Body Irradiation
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning.
|
| pubmed:affiliation |
Department of Medical Oncology and Hematology, University of Toronto Allogeneic Blood and Marrow Transplant Program, Toronto, Ontario, Canada.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|